ESMO18: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer
admin 22nd October 2018 Uncategorised 0After batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of positive data, this time in previously untreated patients.
More: ESMO18: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer
Source: fierce